Loading…
← CockpitCompetitor Analysis › 300261.SZ ABA Chemicals Corporation Class AOpen in the cockpit ↗

ABA Chemicals Corporation Class A300261.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Other
Momentum weak 38
Mkt cap
$592M
US dollars, full cap
Free float
62%
of shares outstanding
$/day
$4.33M
20-day average traded
Fwd P/E
405.0×
forward earnings
ROIC−WACC
-10.8 pp
WACC 7.3%
Hurdle
n/a
no reverse DCF
Next earnings
161 days
28 Apr 2027
Close · CNYCN¥4.11
1D-0.7%
1W-6.6%
1M-11.2%
3M-22.2%
6M-26.1%
YTD-38.9%
1Y-48.4%
ATR %3.2%
52w lowhigh49.4% off high

What ABA Chemicals does

Employees: 1,195

ABA Chemicals at a glance

Size ABA Chemicals (300261.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $592M, the 3278th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.11 on 18 Nov 2026.

Performance Over six months the shares fell 26.1%, against -21.0% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 21 in its peer set.

Growth Revenue fell 16.4% over the last twelve months (peer median +0.5%); the operating margin is -23.4% (peer median 9.5%).

Valuation It trades at 405.0× forward earnings against a peer median of 21.4× (most expensive of 10).

Capital Return on invested capital runs 10.8 points below its cost of capital (7.3% WACC).

Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 80300261.SZ 74
Six months, rebased to 100: ABA Chemicals against the median of its 20 peers (local-currency closes).

ABA Chemicals financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.05BCN¥1.30BCN¥1.20BCN¥1.27BCN¥1.99B
Revenue growth—+9%-6%-36%—
Gross profitCN¥138MCN¥201MCN¥146MCN¥264MCN¥571M
EBITDAn/aCN¥30.4M-CN¥42.6MCN¥71.4MCN¥391M
Net income-CN¥419M-CN¥160M-CN¥258M-CN¥82.3MCN¥203M
Free cash flow-CN¥22.1M-CN¥125MCN¥58.5M-CN¥256M-CN¥107M
Capital expenditureCN¥180MCN¥129MCN¥143MCN¥232MCN¥190M
Total debtCN¥1.52BCN¥1.33BCN¥1.32BCN¥1.23BCN¥1.10B

Quarterly statements and history in the cockpit →

ABA Chemicals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%0%3015070775AVBP00264430015800241200256230003960048860366931745028776032620460PHN002219BOIAPN300261.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. ABA Chemicals is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%0×200×400×30150730079128776032620460PHN002219BOIAPN300261.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. ABA Chemicals is the large dot.

ABA Chemicals competitors and peer comparison

How ABA Chemicals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

ABA Chemicals against its 20 peers (data as of 18 Nov 2026)
Measure300261.SZPeer medianRank in peer set
1-month return-11.2%-9.8%10th lowest of 21
6-month return-26.1%-21.0%8th lowest of 21
Distance from 52-week high-49.4%-41.8%7th lowest of 21
Revenue growth (TTM)-16.4%+0.5%3rd lowest of 20
Operating margin-23.4%9.5%3rd lowest of 21
Forward P/E405.0×21.4×most expensive of 10
ROIC minus cost of capital-10.8 pp-0.1 pp2nd lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
ABA Chemicals 300261.SZChina$592M-26%-16%-23%405.0×n/an/a
Hangzhou Minsheng Healthcare 301507.SZChina$583M-23%+21%11%45.4×19.1%+12.1%
CK Life Sciences International (Holdings) 0775.HKHong Kong$613M-30%0%0%n/an/an/a
ArriVent BioPharma AVBPUnited States$564M-60%n/a-3,620%n/an/an/a
Lanzhou Foci Pharmaceutical 002644.SZChina$548M-9%+6%6%n/a15.4%+6.5%
Shanxi Zhendong Pharmaceutical 300158.SZChina$641M-22%-28%-25%n/an/an/a
Hunan Hansen Pharmaceutical 002412.SZChina$532M-2%-4%21%n/a1.4%+7.0%
Brother Enterprises 002562.SZChina$668M-33%+8%4%n/a4.0%+13.5%
Shanghai Kaibao Pharmaceutical 300039.SZChina$703M-20%-14%22%n/a0.4%+4.8%
Tianjin Tianyao Pharmaceuticals 600488.SSChina$718M-36%-12%3%n/a2.1%-1.3%
Lionco Pharmaceutical 603669.SSChina$474M+4%-6%-17%n/an/an/a
Myung in Pharm 317450.KSSouth Korea$466M-20%+7%35%n/an/an/a
Sirio Pharma 300791.SZChina$759M-6%-9%1%16.2×14.1%+15.6%
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%7.6×n/an/a
TSI 603262.SSChina$842M-46%+3%14%47.7×24.3%+13.4%
Sihuan Pharmaceutical 0460.HKHong Kong$856M-34%+30%15%8.7×n/an/a
Tibet Aim Pharm 002826.SZChina$407M-22%+13%14%n/a0.4%+1.0%
PharmaNutra PHN.MIItaly$922M+2%+17%22%33.5×4.7%+18.5%
New Journey Health Technology Group Co., Ltd.Class A 002219.SZChina$942M-18%-14%8%182.0×n/an/a
Boiron BOI.PAFrance$367M-31%-2%5%9.3×-0.8%-0.5%
Applied Nutrition APN.LUnited Kingdom$986M+31%+51%25%21.4×24.6%+38.5%

Questions

Which companies are ABA Chemicals's closest peers?
The cockpit's peer set: Hangzhou Minsheng Healthcare (301507.SZ), CK Life Sciences International (Holdings) (0775.HK), ArriVent BioPharma (AVBP), Lanzhou Foci Pharmaceutical (002644.SZ), Shanxi Zhendong Pharmaceutical (300158.SZ), Hunan Hansen Pharmaceutical (002412.SZ), Brother Enterprises (002562.SZ), Shanghai Kaibao Pharmaceutical (300039.SZ).
Is ABA Chemicals expensive compared with its peers?
On forward p/e it trades at 405.0× against a peer median of 21.4×, most expensive of 10 in its peer set.
How has ABA Chemicals stock performed?
Over six months to 18 Nov 2026 the shares returned -26.1% against -21.0% for the median peer; over one year -48.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.